Deb Pratik Q
Department of Pathology, Immunology & Laboratory Medicine, Rutgers-New Jersey Medical School, 185 S. Orange Ave, 07103 Newark, NJ USA.
Indian J Hematol Blood Transfus. 2023 Apr;39(2):237-244. doi: 10.1007/s12288-022-01581-7. Epub 2022 Oct 11.
The majority of neoplasms of the breast are derived from epithelial components and give rise to carcinoma, namely invasive ductal and lobular carcinoma of the breast. Unlike carcinomas, primary hematolymphoid malignancies of the breast are a rare group of malignant neoplasms. Due to their rarity, these patients' epidemiological features and outcomes have not been studied well. A few limited case series and case reports suggest that this group of heterogeneous neoplasms has female predominance and poor prognosis. However, no systematic study exists to date. In order to bridge this knowledge gap, the National Cancer Institute's Surveillance, Epidemiology, and End Results databases have been quarried and analyzed to investigate the epidemiological and outcome features of primary hematolymphoid malignancies of the breast. This study is one of the first efforts to establish a systematic understanding of the demographic characteristics and the survival features of this rare group of malignancies.
大多数乳腺肿瘤起源于上皮成分,可引发癌症,即乳腺浸润性导管癌和小叶癌。与癌不同,乳腺原发性血液淋巴系统恶性肿瘤是一组罕见的恶性肿瘤。由于其罕见性,这些患者的流行病学特征和预后尚未得到充分研究。少数有限的病例系列和病例报告表明,这组异质性肿瘤以女性为主,预后较差。然而,迄今为止尚无系统性研究。为了填补这一知识空白,我们对美国国立癌症研究所的监测、流行病学和最终结果数据库进行了挖掘和分析,以研究乳腺原发性血液淋巴系统恶性肿瘤的流行病学和预后特征。本研究是首批旨在系统了解这一罕见恶性肿瘤群体的人口统计学特征和生存特征的努力之一。